Diagnostic Value of C-reactive Protein and White Blood Cell Counts for Early Detection of Inflammatory Complications After Open Resection of Colorectal Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ignazio Tarantino, Cantonal Hospital of St. Gallen
ClinicalTrials.gov Identifier:
NCT01221324
First received: October 14, 2010
Last updated: February 10, 2012
Last verified: February 2012
  Purpose

Although widely used, there is a lack of evidence concerning diagnostic value of C-reactive protein (CRP) and white blood cell counts (WBC) in the postoperative course. The aim of this study was to evaluate the diagnostic accuracy of CRP and WBC for postoperative inflammatory complications after open resection of colorectal cancer.


Condition
Given Indication for Open Resection of Colorectal Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective

Resource links provided by NLM:


Further study details as provided by Cantonal Hospital of St. Gallen:

Primary Outcome Measures:
  • postoperative inflammatory complications [ Time Frame: 30 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Anastomotic leakage [ Time Frame: 60 days ] [ Designated as safety issue: No ]

Enrollment: 1200
Study Start Date: November 2010
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Patients after open resection of colorectal cancer

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Given indication for resection of colorectal cancer

Criteria

Inclusion Criteria:

  • all patients with resection of colorectal cancer

Exclusion Criteria:

  • lack of measurement of C-reactive protein
  • lack of measurement of white blood cell counts
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01221324

Sponsors and Collaborators
Cantonal Hospital of St. Gallen
Investigators
Principal Investigator: Rene Warschkow, MD Cantonal Hospital St. Gallen
  More Information

Publications:
Responsible Party: Ignazio Tarantino, M.D., Cantonal Hospital of St. Gallen
ClinicalTrials.gov Identifier: NCT01221324     History of Changes
Other Study ID Numbers: EKSG10/126
Study First Received: October 14, 2010
Last Updated: February 10, 2012
Health Authority: Switzerland: Ethikkommission

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases

ClinicalTrials.gov processed this record on August 21, 2014